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ABSTRACT
Current treatment schemes of childhood cancer are usually effective enough to enable successful management of the 
disease. With the high rates of survival, another problem arises because patients often suffer much later from side effects 
of the toxic therapy. A common complication caused by cancer treatment is impairment of the female reproductive system 
including dysfunction of the hypothalamus and hypophysis, the killing of gonadal cells, and uterine injury. This may lead 
to altered pubertal timing, gonadotropin insufficiency or deficiency, acute ovarian failure, premature ovarian insufficiency, 
sexual dysfunction, and complicated pregnancy. The severity of these side effects depends a lot on the patient’s age at 
treatment and the particularities of their chemo- and/or radiotherapy regimens.
While some types of cancer require aggressive treatment, and therefore negative side effects cannot be avoided, strategies 
which preserve the patient’s reproductive potential are essential. Such strategies are more established in the treatment 
of adult women, however there are also promising opportunities in the treatment of pediatric oncology patients. Ovar-
ian transposition is already widely applied before pelvic radiotherapy. Cryopreservation of ovarian tissue, cryopreservation 
and in vitro maturation of immature oocytes, or cryopreservation of mature oocytes when the patient’s age is appropriate, 
have also shown to have promising results in pediatric patients. Concurrent combinations of several techniques can also 
be successful.
Counselling of pediatric patients and their families is challenging, and the urgent commencement of anticancer therapies 
often discourages attempts to preserve the girl’s reproductive system. Given that successful methods of fertility preserva-
tion are already accessible, it is crucial not to leave this topic aside at the time of diagnosis.
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INTRODUCTION
Each year about 15,000 children (0–15 years), 20,000 ado-
lescents and young adults (15–24 years) in Europe hear the 
diagnosis of cancer. Fortunately, current treatment schemes 
are effective enough to enable successful management of 
the disease, therefore survival of these patients at 5 years 
after diagnosis is about 80% [1].
Considering outcomes, three groups of childhood can-
cers can be distinguished: good, poor and very poor progno-
sis. The first group has higher than 85% survival rate after 
5 years from diagnosis and includes acute lymphoblastic 
leukaemia, lymphomas, retinoblastoma, renal tumours. To 
manage these diseases multidisciplinary schemes including 
intensive modes of cytotoxic drugs are usually used. Acute 
myeloid leukaemia, some central nervous system (CNS) 
tumours, bone and soft tissue sarcomas, neuroblastoma 
have poor prognosis with a 5-year survival less than 50%. 
Diffuse intrinsic pontine glioma, high-risk neuroblastoma 
and metastatic sarcomas have extremely poor prognosis [2]. 
Overall, many childhood cancer survivors have all the 
life ahead. However, they may suffer late side effects of tre-
atment, which significantly impair the quality of life. Among 
other organs and tissues, reproductive system is usually af-
fected which may cause not only metabolic, immunological 
or growth impairment but also a psychosocial disfunction. 
Even knowing about the risk of possibile infertility extremely 
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affect well-being and intimate relationships of adolescent 
or young adult childhood cancer survivors [3]. This reveals 
a crucial importance to preserve a good state of the repro-
ductive health in every pediatric oncologic patient. 
MECHANISMS  
OF REPRODUCTIVE SYSTEM IMPAIRMENT
Reproductive late effects in female survivors of chil-
dhood cancer include altered pubertal timing (precocious, 
early, rapid tempo, delayed), gonadotropin insufficiency or 
deficiency, acute ovarian failure (AOF), premature ovarian in-
sufficiecy (POI), uterine growth impairment and/or vascular 
injury, vaginal fibrosis or stenosis, sexual dysfunction, dys-
pareunia, complicated pregnancy [4].
All women have a non-renewable pool of follicles from 
birth, thus the potential of fertility is limited by available 
oocytes. A peak in primordial follicles number (6–7 million) 
present in 20-weeks female fetus. Following the progresive 
atresia, the quantity of oocytes decline to 1–2 million at birth 
and 400,000–600,000 at menarche, leading to menopause 
with less than 1000 remaining follicles [5].
The pool of primordial follicles may be substantially 
diminished by cancer treatment through its associated cell 
kill [6] leading to AOF or POI. AOF is a loss of ovarian function 
within 5 years after diagnosis and manifest as amenorrhea 
or lack of pubertal development in a prepubertal girl. POI 
means termination of menses before the age of 40, following 
years of a normal ovarian function (“fertile window“) [4]. The 
number of oocytes decline with the age according to normal 
physiology, therefore the older the ovary, the higer the risk 
of acute failure. On the contrary, younger age at treatment 
seems to be a partially protective factor due to higher num-
ber of primordial follicles at the time of toxic agents exposi-
tion [7]. Childhood Cancer Survivor Study (CCSS) revealed 
that AOF appears in a relatively small number of childhood 
cancer survivors (6,3%) [8]. More commonly, young women 
after cancer treatment present with POI — this occurs much 
more often in childhood cancer survivors than in control 
group (8% vs. 0,8%) [9]. Postmenopausal levels of follicle-
-stimulating hormone (FSH) (as defined by the measuring 
laboratory) in the background of irregular menses before 
age 40 years is a signal of increased speed of follicles atresia 
and ovarian failure. Generally the risk of subfertility can be 
classified according to the type of cancer and its associated 
treatment (Tab. 1).
Impact of radiotherapy 
Brain tumours, such as meduloblastoma, astrocytoma, 
poorly differenciated neuroectodermal tumours and others, 
in addition to surgery usually require cranial irradiation. The 
injury of hypothalamus and hypophysis leads to endocrine 
dysfunction impairing pubertal development, menstrual re-
gulation and reproductive function. It is known that immature 
hypothalamus is more radiosensitive than postpubertal one 
[10]. Precocious puberty is the most common consequence 
in girls following 18–24 Gy radiation. Such doses activate 
hypothalamus which secretes gonadotropin-releasing hor-
mone (GnRH) in a pulsatile way, thus influencing hypophysis 
to produce gonadotropins and stimulate ovaries [11]. In con-
trast, 40-50 Gy or even 30 Gy doses of radiation might directly 
injur hypothalamus-pituitary-gonadal axis. This exposition 
before or during pubertal development more commonly 
cause central hypogonadism which presents as a pubertal 
delay and interruption of maturation with oligomenorrhoea 
or amenorrhoea. Doses of 40 Gy or higher lead to hyperpro-
lactinaemia, which can also cause amenorrhoea [10–12]. 
Pelvic and abdominal irradiation directly affects ovaries 
and uterus. Pediatric tumours, such as pelvis Ewing sarcoma, 
rhabdomyosarcoma of the bladder, vagina or uterus, soft tis-
sue sarcomas are managed with pelvic radiotherapy. Wallace 
et al. using Faddy-Gosden mathematical model investigated 
that the dose able to destroy half of the immature oocytes 
(LD50) is less than 2 Gy [13]. Irradiation induces apopto-
sis and causes direct mitochondrial deoxyribonucleic acid 
(DNA) lesions in oocytes, damages blood vessels, impairs 
neovascularization and causes focal fibrosis in ovaries [14]. 
These mechanisms accelerate physiological follicular pool 
depletion and impair ovarian endocrine function. Wallace 
et al. also found that the effective sterilizing dose (ESD), or 
dose of fractionated radiotherapy at which ovarian failure 
Table 1. Risk of subfertility after treatment of different types of childhood cancers [7]
Low risk (< 20%) Medium risk High risk (> 80%)
•	 Acute lymphoblastic leukaemia
•	 Wilms‘ tumour
•	 Soft tissue sarcoma: stage I
•	 Germ-cell tumours (with gonadal 
preservation and no radiotherapy)
•	 Retinoblastoma
•	 Brain tumour: surgery only, cranial 
irradiation < 24 Gy
•	 Acute myeloblastic leukaemia 
•	 Hepatoblastoma
•	 Osteosarcoma
•	 Ewing‘s sarcoma: non-metastatic
•	 Soft tissue sarcoma: stage II or III
•	 Neuroblastoma
•	 Non-Hodgkin lymphoma
•	 Hodgin‘s lymphoma: alternating treatment
•	 Brain tumour: craniospinal radiotherapy, 
cranial irradiation > 24 Gy 
•	 Whole-body irradiation
•	 Localised pelvic radiotherapy
•	 Chemotherapy conditioning for bone-
marrow transplantation
•	 Hodgkin‘s disease: treatment with 
alkylating-drugs
•	 Soft-tissue sarcoma: stage IV (metastatic)
•	 Ewing‘s sarcoma: metastatic
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occurs immediately after treatment in 97.5% of patients, 
decreases with increasing age at treatment. ESD at birth 
was estimated to be 20.3 Gy; at 10 years 18.4 Gy; at 20 years 
16.5 Gy; at 30 years 14.3 Gy [13]. Some patients even with 
normal menstrual cycle after radiotherapy may present 
with a decreased concentration of anti-Müllerian hormone 
(AMH). Since AMH is an accurate index of ovarian rese-
rve, these women have a high risk of POI [15–16]. There is 
no sufficient technique to estimate the duration of „fertile 
window“, therefore it is essential to predict and early detect 
a compromised ovarian function. Anticipation of shortened 
reproductive time may be helpful for family planning and 
expecting the necessity for hormone therapy in the future.
Pelvic irradiation in childhood negatively affect uterus, 
increasing risk of spontaneous miscarriages, preterm la-
bor, low-birth-weight infants, placental abnormalities [17]. 
These pregnancy-related complications are related with 
reduced uterine volume, damage of uterine vessels, myome-
trial fibrosis, endometrial injury. Insufficient vascularization 
reduce uterine response to cytotrophoblast invasion and de-
crease fetoplacental circulation of blood, thus fetal growth 
is impaired. Injury of endometrium worsen decidualization 
process, therefore placental attachment disorders such as 
placenta accreta or placenta percreta may occur. It is even 
speculated that radiotherapy may cause diffuse thinning of 
the myometrium and increase risk of uterine rupture during 
pregnancy. Prepubertal uterus is more sensitive to pelvic 
irradiation than adult uterus and doses of approximately 
14 to 30 Gy may lead to irreversible uterine dysfunction [18]. 
In younger than 6-year-old patients uterus is injured much 
more severe than ovaries [19]. 
Impact of chemotherapy 
Chemotherapeutic agents have been classified into 
three risk categories, according to their gonadal toxicity 
(Tab. 2).
The alkylating agents create covalent junctions between 
DNA chains, interfere with cleavage during DNA replication 
and cause disruption of cell division, thus directly injuring 
oocytes [20] whereas other drugs, such as docetaxel, destroy 
ovarian-somatic cells with secondary oocyte death [21]. 
Reproductive outcomes also depend on treatment regime, 
cumulative dose, age at treatment and ovarian reserve [4, 6]. 
Even less gonadotoxic agents may reduce follicles pool or 
induce AOF if used in combinations. 
Due to the different protocols of chemotherpeutic tre-
atment an oncological disease itself might be a predictor 
of ovarian injury. Hodgkin lymphoma is considered as a risk 
factor of ovarian failure with the rate reaching 50% [20]. 
The systematic review, including 45 studies, revealed that 
median age at menopause is 33.5 years in Hodgin lym-
phoma survivors. The highest prevalence of amenorrhoea 
was reported in the group of patients exposed to MVPP 
(chlormethamine, vinblastine, procarbazine and predni-
sone) –39–79%. Amenorrhoea rate in Hodgin lymphoma 
survivors treated with ABVD (adriamycin, bleomycin, vinbla-
stine, dacarbazine) protocol seems to be not higher than the 
control population (0-3,8%). After MOPP (chlormethami-
ne, oncovin, procarbazine and prednisone) chemotherapy, 
amenorrhoea rates of 25–79% were reported [6]. In contrast, 
pediatric acute myeloid leukemia has a relatively low risk of 
ovarian failure and infertility as treatment protocols used for 
this disease include anthracyclines and citrabine but not 
alkylating agents. Most acute myeloid leukemia survivors 
in the study of Molgaard-Hansen et al. had normal pubertal 
development and fertility, however 13% of postpubertal fe-
males presented with decreased AMH levels [22]. Only a 10% 
premature ovarian failure incidence have been reported 
after chemotherapeutic treatment for acute lymphoblastic 
leukaemia in prepubertal patients, while high rates of ova-
rian insufficiency were reported among adolescents and 
adults with this type of cancer [20]. 
Bone marrow transplantation is undoubtedly associated 
with the highest risk of ovarian failure and impaired puber-
tal development, while high-doses of cyclophosphamide 
with or without busulfane are used prior to transplantation. 
Only less than 5% of such patients report childbearing after 
treatment [23–24]. Fertility is less affected in patients who 
undergo transplant as young adults (15–30 years) and get 
only cyclophosphamide based conditioning regimens [23]. 
Although conditioning regimens used for children are main-
ly myeloablative (87%), the proportion of pediatric patients 
receiving reduced-intensity/toxicity conditioning regimens 
has increased from 8% in 2000 to 16% in 2015 [24]. Risk-
-adapted chemotherapy combinations reducing cumulative 
dose of alkylating agents and including less gonadotoxic 
Table 2. Risk categories of various chemotherapeutic drugs according to their gonadotoxicity [20]
High risk Alkylating agents (cyclophosphamide, busulphan, chlorambucil, procarbazine, melphalan, ifosfamide, chlormethamine)
Medium risk Platinum agents (cisplatin, carboplatin); anthracycline antibiotics (adriamycin [doxorubicin]); taxoids (docetaxel and paclitaxel)
Low risk Vinca plant alkaloids (vincristine and vinblastine); anthracycline antibiotics (bleomycin), antimetabolites (methotrexate, 5-fluorouracil, 6-MP [mercaptopurine])
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drugs are more and more widely used taking into conside-
ration future outcomes. Unfortunatelly, an agressive and 
gonatotoxic treatment still cannot be avoided in patients 
with advanced cancers with poor prognosis. 
FERTILITY PRESERVATION
Ovarian transposition (oophoropexy) 
Rhabdomyosarcomas of the bladder, vagina and uterus, 
pelvic soft tissue or bone sarcomas such as Ewing‘s sarco-
ma, which require radiotherapy implicating pelvis, are the 
most common indications for oophoropexy. The position of 
ovaries is decided by surgeon and radiotherapist according 
to the radiotherapy plan. Ovarian transposition is often 
performed after neoadjuvant chemotherapy to indicate che-
mosensivity of the tumour and control the disease [19, 25]. 
Ovaries can be transposed via laparotomy together with sur-
gical removal of the tumour or via laparascopy, which is the 
best choice when surgery is not indicated. The gonads are 
sutured to the peritoneum and marked with metallic clips in 
order to be detected in radiographs. After cure from cancer, 
ovaries can be surgically moved into their previous position 
to allow spontaneous pregnancy in the future [26]. The com-
plications of ovarian transposition include ovarian torsion, 
pelvic adhesions leading to tubal or bowel obstruction, 
severe dyspareunia after retrouterine transposition, ovary 
displacement which can impair fertility and future assisted 
reproductive techniques. Moreover, radiation scattering and 
unavoidable movements of ovaries, reduce the reliability 
of this method. Even after transposition, gonads should be 
kept away from the radiation field with approximately 2 cm 
of organ at risk volume margins [27]. Oophoropexy should 
be performed as close to the beginning radiotherapy as 
possible, due to the risk of ovarian remigration.
Gonadotropin releasing hormone analogues 
(GnRHa)
Theoretically, GnRHa create pseudoprepubertal condi-
tions by inhibiting hypothalamic-pituitary-ovarian axis, thus 
making ovaries suppressed and less sensitive to gondatoxic 
agents. A direct antiapoptotic effect on ovarian germline 
stem cells has also been noticed [28]. However, GnRHa can-
not be applied to pre-pubertal girls while their follicles are 
immature and ovarian cycle is not settled. Post-pubertal 
patients may benefit on this method, however there is lack 
of studies revealing the impact on ovarian suppression for 
adolescents. While not enough evidence of efficacy and 
possible harm is currently available, this method is not ro-
utinely recommended for pediatric patients [25]. 
Embryo cryopreservation
It is a worldwide routinely used technique with satis-
factory number of pregnancies. However, approximately 
2–3 weeks are needed for ovarian stimulation and such 
treatment delay is not always acceptable. Most importantly, 
since sperm is necessary for the creation of embryos, this 
method is only applicable for adults.
Cryopreservation of mature oocytes
This method is well-developed and no longer consi-
dered experimental [29–30]. Currently, more flexible ran-
dom-start protocols are available for ovarian stimulation. 
Therefore in most cases there is no need to wait for a cer-
tain day of the menstrual cycle and the delay of treatment 
initiation is lesser to compare with older methods. Current 
vitrification techniques allow perfect oocyte survival and 
following normal development. Noyes et al. in 2009 repor-
ted 900 newborns after oocyte cryopreservation [31]. Rate 
of congenital anomalies was not higher than in normally 
conceived babies population. Disadvantages of this method 
include potential side effects of the hormonal interventions, 
necessity of endovaginal access to retrive oocytes, unava-
ilability for pre-pubertal patients [25, 30].
In vitro maturation (IVM) of immature oocytes 
This strategy has been used mostly in adult women in 
addition to mature oocytes retrieval, to maximize the number 
of cells suitable for in vitro fertilization (IVF), as well as for the 
patients who cannot undergo a stymulated cycle, have poli-
cystic ovaries syndrome or need immediate cancer treatment. 
Although multiple pregnancies have been achieved with this 
technique and results are improving, the overall success rate 
remains lower than in conventional IVF. IVM can be considered 
as an additional technique to ovarian tissue cryopreservation 
and autotransplantation. However, further investigation on 
this topic is necessary. Currently IVM is considered experi-
mental, especially for children [26]
Ovarian tissue cryopreservation
A small portion of ovarian cortical tissue or the whole 
ovary can be cryopreserved and transplanted later or used 
to retrieve immature oocytes for in vitro maturation [29]. 
Sexual maturity is not necessary for the procedure, therefore, 
although considered experimental, this method is currently 
the only possible option for fertility preservation in prepu-
bertal patients. Ovarian tissue cryopreservation may show 
good results when offered to the patients with the highest 
risk of POI but likely to survive. For this evaluation Wallace 
et al. suggested to use Edinburgh selection criteria (Tab. 3). 
At least 80 pregnancies have been reported by far after 
autotransplantation of cryopreserved adult ovarian tissue 
with pregnancy rate 23–37% [33]. Demeestere et al. in 
2015 reported the first live birth after autotransplantation 
of ovarian tissue which was obtained from adolescent girl 
before the onset of menarche [34]. Return of hormonal 
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function after ovarian tissue autotransplantation allow to 
achieve puberty induction and onset of menses [35]. Ova-
rian transposition and ovarian tissue cryopreservation are 
sometimes combined [27, 36]. Autograft can be stored in 
liquid nitrogen at –196 oC for more than ten years [36]. 
Later the tissue can be returned into pelvis and fixed to the 
remaining ovary, peritoneum of ovarian fossa or broad liga-
ment, theoretically allowing natural conception. However, 
ortotopic transplantation is a highly invasive laparoscopic 
or even laparotomic procedure [26, 29, 33, 36], which may 
be complicated due to pelvic adhaesions after radiotherapy. 
Heterotopic transplantation to, e.g. forearm, abdominal wall 
or chest wall, is technically easier, allows better access for 
oocyte retrieval and follicular monitoring. Studies showed 
good results with restored ovarian function and follicular de-
velopment [37–38]. The first clinical pregnancy and delivery 
of twins following heterotopic grafting of cryopreserved 
ovarian tissue has been reported in 2013 [38]. However, IVF is 
unavoidable to achieve pregnancy in these cases. Vability of 
autografts can be impaired due to poorer neovascularization 
in heterothopic position [26, 34, 36]. A theoretical possibility 
of cancer cells reintroduction with ovarian tissue autograft 
must be considered, especially for the patients with leuka-
emia [39]. Although so far any reports of cancer recurrence 
have been published, laboratory tests should be performed 
to exclude possible malignancy [39]. Some research with 
artificial ovary created of three-dimensional (3D) alginate 
matrigel matrix and filled with patient‘s follicles has shown 
satisfactory results in animals. This promising technique wo-
uld allow to avoid risk of reimplanting malignant cells [26]. 
COUNSELLING
Effects on girl‘s pubertal development and future fertility 
should be discussed before the treatment plan is confirmed. 
Multidisciplinary team including oncology and reproduc-
tive medicine services or even mental health specialists is 
essential to achieve satisfactory results. American Society 
of Clinical Oncology (ASCO) recommends clear points for 
a discussion of infertility and fertility preservation with a pa-
tient, parents or guardians (Tab. 4). 
Established methods of fertility preservation for pedia-
tric patients should be innitally proposed. Information about 
currently investigational methods or available experimental 
protocols should be also provided, especially in cases, when 
convenional techniques are not appropriate [39]. However, 
a PanCare project survey revealed that counselling of such 
patients is not established enough: from 198 European in-
stitutions which provided haemato-oncology treatment 
to children, only 68 institutions responded to questiona-
ire and pretreatment fertility counselling was offered by 
64 institutions. Only one third of them worked by a team 
while patients in other institutions were counselled only 
by oncohemathologist [40]. Another study showed similar 
results: in 38 centers which responded to their survey 39% 
of patients were councelled and only 29% received fertility 
preservation programs [41]. 
The time necessarry for fertility preservation procedu-
res have to be balanced with the beginning of potentially 
life-saving anticancer therapies, leading to extreme family 
stress. Given their preference on intiating cancer manage-
ment, pediatric oncology providers might not pay enough 
attention on reproductive issues, thus discouraging these 
families on attempts to preserve fertility before treatment. 
Similarly, reproductive specialists may lack competence with 
aspects of particular oncologic diagnosis. A majority of ferti-
lity preservation techniques are considered experimental in 
children, therefore no guarantees of success can be given to 
the patient‘s family. To solve the current problems, PanCare 
LIFE project including experts form various European and 
non-European countries is currenly working on universal 
and cohesive guidelines for fertility issues of pediatric pa-
tients facing gonadotoxic therapies [42]. 
CONCLUSIONS
Considering high survival rates of pediatric cancer and 
risk of reproductive health impairment, it is crucial not to 
leave this topic aside at the time of oncologic diagnosis. 
Table 3. Edinburgh criteria for selection for ovarian tissue 
cryopreservation [32]
•	 Age < 35 years
•	 No previous chemotherapy or radiotherapy (patients 
aged < 15 years with previous low-risk chemotherapy should be 
considered)
•	 Realistic chance of surviving for at least 5 years
•	 High risk of treatment-induced immediate ovarian failure 
(estimated > 50%)
•	 Informed consent from patient or (in the case of an incompetent 
child) from parents
•	 Negative HIV*, syphilis, hepatitis serology
•	 Not pregnant, no existing children
*Human immunodeficiency virus
Table 4. Points for a discussion of infertility and fertility preservation 
with a patient (or parents or guardians) according to ASCO Practise 
Guideline [39]
•	 Inform patient of individual risk
•	 Discuss common concerns:
 — Options of fertility preservation
 — Risk of delaying treatment
 — Costs necessary for fertility preservation procedures
 — Pregnancy risks after cancer
•	 Refer to appropriate specialists (e.g. reproductive specialists, 
mental health professionals, etc.)
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Several current methods of fertility preservation have alre-
ady showed good results while some of them are still being 
developed. Further studies on reducing gonadotoxicity of 
cancer treatments and preserving reproductive function 
are necessary to improve counselling and management 
of these patients, including all the aspects of the disease.
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